Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Jensen Huangs admitted affair with a business executive and the Nvidia boards independent investigation have drawn attention, with traders debating whether the unverified espionage allegations and potential leadership fallout pose a serious risk or are an overreaction unrelated to Nvidias AI business. Many are buying the selloff on confidence in the companys fundamentals, while others remain cautious about the investigation and possible CEO succession concerns.

IBRX is selling off after a weaker-than-expected Q3 report, with traders focused on the revenue decline, slowing commercial uptake and possible future dilution. The reaction is mixed: critics question execution and the cash outlook, while bullish traders argue the positive BCG-naive trial result and Israeli approval support the longer-term Anktiva story.

Trade Desk shares are rallying into quarterly earnings, with traders pointing to heavy short interest and the possibility of a squeeze if results or guidance beat expectations. Some speculate about an earnings leak, but that is unconfirmed; others warn the pre-earnings pop could fade, citing the stocks history of sharp post-report moves.

Q3 earnings expectations and Hims & Hers Eli Lilly partnership, which brings Zepbound and Foundayo onto its platform, are driving attention. Traders debate whether the added branded-drug business can offset expected margin pressure, while the stocks sharp swings have fueled unverified earnings-leak speculation.

Clovers Q3 earnings beat and improved full-year outlook, alongside a profitable quarter and strong membership growth, are fueling renewed buying and a push to hold above $5. Traders are divided over whether the gains can stick, with some focused on the companys growth and others disappointed by the lack of concrete Counterpart Health software revenue updates.

Webulls China-related scrutiny, including a congressional report alleging undisclosed ties and subsequent securities lawsuits, is dominating discussion amid a prolonged share-price decline. Traders disagree over whether the concerns are misleading or a genuine overhang; bullish holders cite the companys growth and upcoming earnings, while bearish voices remain focused on the risk of further losses.

TG Therapeutics BRIUMVI-driven quarterly beat and raised revenue outlook are drawing attention, but shares have fallen as traders debate a sell-the-news reaction versus a buying opportunity. The upcoming Phase 3 readout for subcutaneous BRIUMVI is widely viewed as the next major catalyst.

QXO is drawing attention after preliminary third-quarter results showed strong growth, largely reflecting its acquisitions, and CEO Brad Jacobs struck an upbeat tone on a conference call. Bulls welcomed the update as evidence the building-products roll-up is progressing, while some remain concerned about integration, dilution and the companys long-term strategy.

Capricor is drawing attention ahead of the FDAs November 22 decision on deramiocel for Duchenne muscular dystrophy, with the application now focused on preserving upper-limb function and 28 HOPE-3 investigators urging approval. Many traders are bullish on the data and physician support, while others see substantial rejection risk; the advisory committees negative vote concerned the cardiac indication, not the upper-limb case.

Traders are linking ARWRs sharp decline to weak early sales for rival Ioniss Tryngolza, raising concerns about the commercial outlook for Arrowheads Redemplo despite some arguing its data and product profile are stronger. Others point to Arrowheads high cash burn and possible financing needs as added pressure.